Table 3.
Monitor unit per fraction and total segments in each of the studied cases using XiO, Prowess, and KonRad TPSs.
| Total Segments | MU/fx | |||||
|---|---|---|---|---|---|---|
| KonRad | Prowess | XiO | KonRad | Prowess | XiO | Tumor Site |
| 67 | 35 | 96 | 432 | 284 | 513 | Low‐grade Glioma |
| 51 | 60 | 88 | 355 | 304 | 523 | Parotid Carcinoma |
| 48 | 84 | 79 | 381 | 489 | 548 | Pituitary Adenoma |
| 57 | 72 | 120 | 377 | 463 | 595 | Retinoblastoma |
| 61 | 48 | 81 | 372 | 411 | 379 | Parotid Carcinoma (carsinoma carcinoma) |
| 71 | 84 | 109 | 481 | 428 | 742 | High‐risk Medulloblastoma (Posterior fossa) |
| 48 | 42 | 114 | 342 | 327 | 724 | Low‐risk Medulloblastoma (Posterior fossa) |
| 42 | 49 | 78 | 338 | 361 | 591 | Nasolaboil RMS |
| 100 | 98 | 203 | 713 | 374 | 911 | Rhabdomyosarcoma (RMS) |
| 84 | 42 | 96 | 363 | 292 | 512 | Ependymoma |
| 100 | 108 | 237 | 682 | 449 | 1167 | Maxillary Sarcoma |
| 66.3 | 65.6 | 118 | 439.6 | 380 | 655 | Mean |
| 20.5 | 25 | 52.8 | 134.2 | 72.6 | 222 | SD |
| 7.864 | 9.5 | F‐test | ||||
| 0.002 | 0.001 | p‐value | ||||